Sathgen completes dosing of first two cohorts of healthy volunteers with MSP008-22, a novel…
The clinical development of this drug is supported and managed by Clinexel Life Sciences
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sathgen Therapeutics
Sathgen Therapeutics announces completion of first cohort in phase 1 clinical trial with anti-cancer…
Sathgen aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate…